Quinestrol

Identification

Name
Quinestrol
Accession Number
DB04575
Description

The 3-cyclopentyl ether of ethinyl estradiol.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 364.5204
Monoisotopic: 364.240230268
Chemical Formula
C25H32O2
Synonyms
  • 17-alpha-Ethinylestradiol 3-cyclopentyl ether
  • 17alpha-Ethynylestradiol 3-cyclopentyl ether
  • Estradiol-17-beta 3-cyclopentyl ether
  • Quinestrol
  • Quinestrolo
  • Quinestrolum
External IDs
  • W 3566
  • W-3566

Pharmacology

Indication

Used in hormone replacement therapy, treating symptoms of menopause such as hot flashes. Also used to treat breast and prostate cancer.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Quinestrol is the 3-cyclopentyl ether of ethinyl estradiol (the active metabolite). After gastrointestinal absorption, it is stored in adipose tissue where it is slowly released and metabolized principally to the parent compound, ethinyl estradiol. Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol.

Mechanism of action

Estrogens diffuse into their target cells and interact with a protein receptor (the estrogen receptor). Estrogen interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

TargetActionsOrganism
AEstrogen receptor alpha
agonist
modulator
Humans
Absorption

Absorbed following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Metabolized principally to the parent compound, ethinyl estradiol. Ethinyl estradiol is metabolized in the liver. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens.

Hover over products below to view reaction partners

Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabQuinestrol may decrease the anticoagulant activities of Abciximab.
AceclofenacAceclofenac may increase the thrombogenic activities of Quinestrol.
AcenocoumarolQuinestrol may decrease the anticoagulant activities of Acenocoumarol.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Quinestrol.
Acetylsalicylic acidQuinestrol may decrease the anticoagulant activities of Acetylsalicylic acid.
AdalimumabQuinestrol may increase the thrombogenic activities of Adalimumab.
AlemtuzumabQuinestrol may increase the thrombogenic activities of Alemtuzumab.
AlirocumabQuinestrol may increase the thrombogenic activities of Alirocumab.
AllantoinThe therapeutic efficacy of Allantoin can be decreased when used in combination with Quinestrol.
AlteplaseQuinestrol may decrease the anticoagulant activities of Alteplase.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

International/Other Brands
Estrovis / Estrovis 4000 / Estrovister / Plestrovis

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrane steroids
Alternative Parents
17-hydroxysteroids / Phenanthrenes and derivatives / Tetralins / Alkyl aryl ethers / Ynones / Tertiary alcohols / Cyclic alcohols and derivatives / Acetylides / Hydrocarbon derivatives
Substituents
17-hydroxysteroid / Acetylide / Alcohol / Alkyl aryl ether / Aromatic homopolycyclic compound / Benzenoid / Cyclic alcohol / Estrane-skeleton / Ether / Hydrocarbon derivative
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
terminal acetylenic compound, 17-hydroxy steroid (CHEBI:8716) / C18 steroids (estrogens) and derivatives (C07619) / C18 steroids (estrogens) and derivatives (LMST02010037)

Chemical Identifiers

UNII
JR0N7XD5GZ
CAS number
152-43-2
InChI Key
PWZUUYSISTUNDW-VAFBSOEGSA-N
InChI
InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1
IUPAC Name
(1S,10R,11S,14R,15S)-5-(cyclopentyloxy)-14-ethynyl-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-trien-14-ol
SMILES
[H][[email protected]@]12CC[[email protected]@](O)(C#C)[[email protected]@]1(C)CC[[email protected]]1([H])C3=C(CC[[email protected]@]21[H])C=C(OC1CCCC1)C=C3

References

General References
Not Available
Human Metabolome Database
HMDB0015579
KEGG Drug
D00576
KEGG Compound
C07619
PubChem Compound
9046
PubChem Substance
46508939
ChemSpider
8694
RxNav
9066
ChEBI
8716
ChEMBL
CHEMBL1201165
ZINC
ZINC000003875993
Therapeutic Targets Database
DAP001016
PharmGKB
PA164749042
Wikipedia
Quinestrol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)107.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.00157 mg/mLALOGPS
logP5.19ALOGPS
logP5.4ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)17.59ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.46 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity108.27 m3·mol-1ChemAxon
Polarizability44.02 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.997
Blood Brain Barrier+0.9483
Caco-2 permeable+0.8214
P-glycoprotein substrateSubstrate0.6542
P-glycoprotein inhibitor INon-inhibitor0.585
P-glycoprotein inhibitor IINon-inhibitor0.8718
Renal organic cation transporterNon-inhibitor0.8168
CYP450 2C9 substrateNon-substrate0.7004
CYP450 2D6 substrateNon-substrate0.9177
CYP450 3A4 substrateSubstrate0.7205
CYP450 1A2 substrateInhibitor0.8321
CYP450 2C9 inhibitorNon-inhibitor0.8873
CYP450 2D6 inhibitorNon-inhibitor0.9494
CYP450 2C19 inhibitorInhibitor0.7307
CYP450 3A4 inhibitorNon-inhibitor0.5178
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.73
Ames testNon AMES toxic0.9105
CarcinogenicityNon-carcinogens0.8635
BiodegradationNot ready biodegradable0.9812
Rat acute toxicity1.9408 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8631
hERG inhibition (predictor II)Inhibitor0.5854
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a59-2920000000-99119dee5db3aab05906

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
Modulator
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Shyu C, Cavileer TD, Nagler JJ, Ytreberg FM: Computational estimation of rainbow trout estrogen receptor binding affinities for environmental estrogens. Toxicol Appl Pharmacol. 2011 Feb 1;250(3):322-6. doi: 10.1016/j.taap.2010.11.005. Epub 2010 Nov 12. [PubMed:21075131]

Drug created on September 07, 2007 15:29 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates